Notably, CDNF treatment not only reduced TXB2 production in platelets but also normalized the levels of stroke-upregulated COX, 12-lipoxygenase (LOX), and CYP450-derived oxylipins to baseline levels. The gene discussed is CDNF; the disease is stroke disorder.